GlassScriptPhysician profile
Elizabeth Roylance Ault
NPI 1619310257
$2,478.99
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84.81 · 2020: $11.51 · 2021: $238 · 2022: $1,227 · 2023: $918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $918.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $918.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $376.27 | 2021-2023 | Vraylar |
| Janssen Pharmaceuticals, INC | $334.36 | 2019-2023 | Spravato |
| Lundbeck LLC | $191.23 | 2021-2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $179.12 | 2022-2023 | Trintellix |
| Alkermes, INC. | $175.78 | 2022-2023 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $168.98 | 2021-2022 | |
| Corium, LLC | $165.73 | 2022-2023 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $148.21 | 2021-2023 | Rexulti, Abilify Asimtufii, Nuedexta |
| Almatica Pharma LLC | $144.20 | 2022-2023 | Loreev Xr |
| Neos Therapeutics, LP | $133.24 | 2022-2023 | Adzenys Xr-Odt |
| Tris Pharma INC | $107.38 | 2021-2023 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $71.40 | 2022-2023 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $71.24 | 2022 | |
| Ironshore Pharmaceuticals INC. | $66.46 | 2022-2023 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $46.53 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $35.73 | 2023 | Amyvid |
| Bausch Health US, LLC | $32.40 | 2022 | |
| Sunovion Pharmaceuticals INC. | $18.01 | 2022 | |
| Alfasigma USA, INC. | $12.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Ault listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.